HIV-1 infection, use of drugs and neuropsychologic efficiency;Infección por VIH, consumo de drogas y rendimiento neuropsicológico

Anales de Medicina Interna

Volumn 22, Issue 12, 2005, Pages 569-574

  Failde Garrido J M ^a   López Castro, José ^b   Fernandez Rodriguez V ^c   Fernandez Rodriguez R ^b  

^a UNIVERSITY OF VIGO   (Spain)

^b Hospital Cristal Pinor   (Spain)

^c Unidad Asistencial de Drogodependencias   (Spain)

Author keywords

HIV; Methadone; Neuropsychology; Use abuse of drugs

Indexed keywords

METHADONE; NARCOTIC AGENT;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; PREVALENCE; SEMI STRUCTURED INTERVIEW; SEROLOGY; ADDICTION; ADULT; COGNITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPSYCHOLOGICAL TEST; PSYCHOMOTOR PERFORMANCE;

ADULT; COGNITION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHADONE; NARCOTICS; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SUBSTANCE-RELATED DISORDERS;

EID: 33644909353     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Centro Nacional de Epidemiología. Vigilancia epidemiological del SIDA en España. Balance de la epidemia a 31 de diciembre de 2004. Informe Semestral no 2. Ministerio de Sanidad y Consumo, 2004.
2. Mann J, Tarantola DJM, Netter TW. AIDS in de world. A global Report Cambridge Massachusetts, and London: Harvard University Press, 1992.
3. Mason KI, Campbell A, Hawkins P, Madhere S, Johnson K, Takushi Chinen R. Neuropsychological functioning in HIV positive African American Women with a history of drug use. J N Med Ass 1998; 90: 665-674.
4. Stern Y. Neuropsychological Asessment of Seropositive Intravenous Drug Users. En I. Grrant & A. Martín (Eds.), Neuropsychology of HIV infection (pp. 221-233). New York: Oxford University Press (1994).
5. Meek PS, Clark HW, Solana VL. Neurocognitive impairment: the unrecognized component of dual diagnosis in substance abuse treatment. J Psycho Drugs 1989; 21: 153-160.
6. Rounsaville BJ, Novelly RA, Kleber HD. Neuropsychological impairment in opiate addicts: Risk factors. Ann New York Acad Sci 1981; 362: 79-90.
7. Wodak A., Capelhorn J, Crofts, N. T cell counts from " methadone" and "nonmethadone" groups. Am J Drug Alc Abuse 1995; 21: 283-284.
8. Carballo-Diéguez A, Sash J, Goetz R. The effect of methadone on inmunological parameters among HIV-positive and HIV-negative drug users. Am J Drug Alc Abuse 1994; 20: 317-329.
9. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction 2000; 95: 687-695.
10. Gerber JG, Rosenkranz S, Segal Y, Aberg, J, D'Amico R, Mildivan D, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Inm Defic Synd 2001; 27: 153-160.
11. Gourevitch MN. Interactions between methadone and medications used to treat HIV infection. Mount Sinai J Med 2000; 68: 227-228.
12. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mount Sinai J Med 2000; 67: 429-436.
13. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic Lohezic F, Riche C. Inhibition of methadone and buprenorphine N-dealkylation by three HIV-1 protease inhibitors. Drug Metab Disp 1998; 26: 257-260.
14. Lezak MD. Neuropsychological assessment (3rd Ed.). New York: Oxford University Press, 1995.
15. Bono G, Mauri M, Sinforiani E, Barbarini G, Minoli L, Fea M. Longitudinal neuropsychological evaluation of HIV-infected intravenous drug users. Addiction 1996; 91: 263-268.
16. Beatty WW, Katzung VM, Moreland VJ, Nixon SJ. Neuropsichological performance of recently abstinent alcoholics and cocaine abusers. Drug Alc Depend 1995; 37: 247-253.
17. Starce F, Baldassarre C, Biancolilli V, Fea M, Serpelloni G, Bartolli L, Maj J. Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsycholgical Study. Act Neuropsych Scand 1998; 97: 132-138.
18. Selnes OA, McArthur JC, Royal W, Updike JL, Nance-Spronson T, Concha M, et al. HIV-1 infection and intravenous drug use: Longitudinal neuropsychological evaluation of asymtomatic subjects. Neurology 1992; 42: 1924-1930.
19. Grassi MP, Clerici F, Perin C, Zocchetti C, Cargneli A. HIV infection and drug use: influence on cognitive function. AIDS 1995; 9: 165-170.
20. Selnes OA, Galai N, Bacellar H, Miller EN, Becker JT, Wesch J, et al. Cognitive performance after progression to AIDS: A longitudinal study from the Multicenter AIDS Cohort Study. Neurology 1995; 45: 267-275.
21. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, et al. Neuropsychology of HIV infection at different disease stages. J Inter Neuropsychol Soc 1995; 1: 231-251.
22. White DA, Heaton RK, Monsch AU, HNRC GROUP. Neuropsychological studies of asymptomatic human immunodeficiency virustype-1 infected individuals. J Inter Neuropsychol Soc 1995; 1: 305-315.
23. Beck, A. Inventario de depresión. Barcelona: Psiké, 1978.
24. Spielberg CD Gorsuch RL, Lushene RE. STAI. Cuestionario de Ansiedad Estado-Rasgo (3 Edición). Madrid: TEA Ediciones, S.A. 1998.
25. Bornstein RA. Methodological and conceptual issues in the study of cognitive change in HIV infection. En I. Grrant & A. Martín (Eds.), Neuropsychology of HIV infection (pp. 146-160). New York: Oxford University Press, 1994.
26. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, et al. Neuropsychological performance in HIV-infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology 1990; 40: 197-203.
27. Heseltine PNR, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 1998; 55: 41-51.
28. Rodríguez Álvarez M, Rodríguez Salgado D. Estudio de la afectación neuropsicológica asociada al VIH: revisión de aspectos metodológicos. Act Esp Psiq 2003; 31: 79-84.
29. Carlin AS. Neuropsychological consecuences of drag abuse. In I. Grant & K. Me. Adams (Eds.), Neuropsychological assessment of neuropsychiatric disorders, (pp. 478-497). New York: Oxford University Press, 1986.
30. Harman DE. Neuropsychological toxicology. New York: Pergamon Press, 1988.
31. Concha M, Graham NMH, Muñoz A, Vlahow D, Royal W, Updike M. Effect of chronic substance abuse on the neuropsychological performance of intravenous drag users with a hig prevalence of HIV-1 seropositivity. Am J Epidemiol 1992; 136: 1338-1348.
32. Hestad K, Aukrust P, Ellertsen B, Klove H. Neuropsychological deficits in HIV-1 seropositive and seronegative intravenous drug users (IVDUs): A follow-up study. Journal of the International Neuropsychol Soc 1996; 2: 126-133.
33. Royal W, Updike M, Selnes OA, Proctor TV, Nance-Spronson L, Solomon L, et al. HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users. Neurology 1991; 41: 1905-1910.
34. Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal JH, et al. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results. Prog Neuropsychopharm Biolog Psych 1991; 15: 649-662.
35. Beatty WW, Borrell GK. Forms of knowledge, cognitive impairment and drug abuse: a demonstration. Prog Neuropsychopharm Biologl Psych 2000; 24: 17-22.
36. Handelsman L, Aronson M, Maurer G, Wiener J, Jacobson J, Bernstein D. Neuropsychological and neurological manifestations of HIV-1 dementia in drug users. Journal of Neuropsychiatry and Clinical Neurosciences 1992; 4: 21-28.
37. McKegney FP, O'Dowd MA, Feiner C, Selwyn P, Drucker E, Friedlan GH. A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients. AIDS 1990; 4: 565-569.
38. Schoenbaum, EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Eng J Med 1986; 321: 874-879.
39. Silverstein CH, McKegnay FP, O'Dowd MA, Selwyn PA, Schoenbaum E, Drucker E, et al. A prospective longitudinal study of neuropsychological and psychosocial factors in asymptomatic individuals at risk of HTLV-III/LAV infection in a methadone program: Preliminary findings. International Journal of Neurosciences 1987; 32: 669-676.
40. Taylor MJ, Alhassoon OM, Schwinsburg BC, Videen JS; Grant I. MR spectroscopy in HIV and stimulant dependence. J Intern Neuropsychol Soc 2000; 6: 83-85.
41. McLachlan C, Crofts N, Wodak A, Crowe S. The effects of methadone on immune function among injecting drug users: a review. Addiction 1993; 88: 257-263
42. Shavit Y, Lewis JW, Terman GW, Gale RP, Liebeskind JC.Opioid peptides mediante the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984; 223: 188-190.
43. Avants SK, Margolin A, McMahon TJ, Kosten TR. Association-between self-report of cognitive imparirment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. Addictive Behaviors 1997; 22: 599-611.
44. Rodríguez Salgado D. Afectación neuropsicológica temprana asociada a la infección por VIH en drogodependientes. Tesis doctoral. Santiago de Compostela: Universidad de Santiago de Compostela, 2000.
45. Vázquez Justo E. Factores que influyen en el rendimiento neuropsicológico de drogodependientes seropositivos al VIH. Tesis doctoral. Santiago de Compostela: Universidad de Santiago de Compostela, 2001.